Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 2312 participants.

Also called NCT05952206

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 2,312 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT05952206
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Belgium, France, Spain (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT05952206. Randomized; no masking; primary purpose treatment. Start 2023-10-13 (actual); primary completion 2027-01-13 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ischemic and Bleeding Outcomes After Angiolite Stent Implantation and an Abbreviated Dual Antiplatelet Therapy
Acronym
ANGIODAPT
Intervention (Device)
Angiolite: Sirolimus-eluting stent
Intervention (Device)
Xience: Everolimus-eluting stent
Intervention (Drug)
1-month DAPT
Intervention (Drug)
12-month DAPT (Standard of care)
Lead sponsor
iVascular S.L.U. (class: industry)

Record details

Record id
cardio:ct-nct05952206
Content hash
27020387db6a95904d680e70b22988a581582cafbe2c3a72bb6de9a0e7892081